ReviewCurrent opinion in infectious diseases2014
Antibiotic therapy of pneumonia in the obese patient: dosing and delivery.
Review in Current opinion in infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Multicentre prospective cohort study of body mass index and postoperative complications following gastrointestinal surgery.The British journal of surgery · 2016Trial
- Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.Intensive care medicine · 2015Trial
- Influence of the dose and duration of intrapartum antibiotic prophylaxis on umbilical cord blood ampicillin levels.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Multidrug-Resistant Infections and Metabolic Syndrome: An Overlooked Bidirectional Relationship.Biomedicines · 2025Review
- Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action.World journal of emergency surgery : WJES · 2023Review
- Clinical Outcomes with Ertapenem for Pneumonia in Obese versus Nonobese Patients.Antimicrobial agents and chemotherapy · 2022Article
- Does Rocuroinum Dose Adjusted Due to Lean Body Weight Provide Adequate Intubation Conditions?: A Prospective Observational Study.International journal of clinical practice · 2022Observational
- Size Matters: The Influence of Patient Size on Antibiotics Exposure Profiles in Critically Ill Patients on Continuous Renal Replacement Therapy.Antibiotics (Basel, Switzerland) · 2021Article
- Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections.Frontiers in pharmacology · 2021Article
- Association of Obesity With Maternal and Cord Blood Penicillin Levels in Women With Group B Streptococcus Colonization.Obstetrics and gynecology · 2020Article
- Calculated initial parenteral treatment of bacterial infections: Pharmacokinetics and pharmacodynamics.GMS infectious diseases · 2020Article
- Evaluation of treatment options for methicillin-resistantInfection and drug resistance · 2019Article
- Article
- Information provision for antibacterial dosing in the obese patient: a sizeable absence?The Journal of antimicrobial chemotherapy · 2016Article
- Therapeutic management of peritonitis: a comprehensive guide for intensivists.Intensive care medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewObesity has been shown to be associated with antibiotic underdosing and treatment failure. This article reviews the recent literature on antibiotic dosing in obese patients with pneumonia. RECENT
findingsObesity is associated with several alterations in antibiotic pharmacokinetics and pharmacodynamics, including increases in the antibiotic volume of distribution and clearance. These alterations necessitate changes in the dosing of certain antibiotics. However, data on antibiotic dosing for pneumonia in obese patients are limited and come mainly from observational studies. Additionally, dosing recommendations are often extrapolated from healthy obese volunteers and from the studies of antibiotics given for other indications. SUMMARY: Recognizing obesity-related pharmacokinetic and pharmacodynamic alterations is important in treating obese patients with pneumonia. Studies that evaluate such alterations and assess the impact of antibiotic dosing and delivery on the clinical outcomes of this patient population are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.